SaNOtize Research & Development Corp.: SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19

Co-led by Horizons Ventures and OurCrowd, new funding enables SaNOtize to invest in its ongoing Phase 3 clinical trial for COVID-19 prevention and enhance clinical development of its other nitric

Related Keywords

United States ,Thailand ,India ,Hong Kong ,Israel ,Singapore ,Vancouver ,British Columbia ,Canada ,Indonesia ,Bahrain ,Sri Lanka ,Canadian ,Chris Miller ,Kostenloser Wertpapierhandel ,Frances Kang ,Sean Gjos ,Jon Medved ,Gilly Regev ,Sanotize Co ,Linkedin ,Twitter ,Lancet Regional Health Southeast Asia ,Central Drugs Standard Control Organization ,Sanotize Research Development Corp ,European Union ,Business Development ,Horizons Ventures ,Nitric Oxide Nasal Spray ,Middle East ,Research Development Corp ,Lancet Regional Health Southeast ,Nitric Oxide Releasing Solution ,Portfolio Curator ,Chief Scientific Officer ,Research Development ,Sanotize ,Research ,Development ,Orp ,Nnounces ,Billion ,Series ,Funding ,Advance ,Mitric ,Xide ,Ased ,Herapeutics ,Ncluding ,Nasal ,Spray ,Treatment ,Prevention ,Covid ,